Preclinical Insights into Bremelanotide's Brain Mechanisms for Boosting Female Sexual Function

Hypoactive Sexual Desire Disorder (HSDD) is a prevalent and distressing condition affecting a significant proportion of premenopausal women, characterized by a persistent or recurrent deficiency or absence of sexual fantasies and desire for sexual activity, causing marked personal distress. Existing pharmacological interventions for HSDD often demonstrate limited efficacy or are associated with undesirable side effects, underscoring a critical unmet need for more effective and well-tolerated therapeutic options. This comprehensive preclinical review synthesizes a vast body of research to elucidate how Bremelanotide, a novel melanocortin receptor agonist, exerts its influence on the central nervous system (CNS) to modulate and enhance female sexual function, addressing a key knowledge gap in its mechanism of action.